designer491/iStock via Getty Images Neurogene ( NASDAQ: NGNE ) has fallen ~35% in after-hours trading Monday after reporting interim phase 1/2 data on pediatrics patients given NGN-401, a gene therapy for the treatment of Rett syndrome. The company is examining the candidate in both low and high.
Back to Health Page
